47 filings
Page 2 of 3
8-K
gpatepu s20zfu
2 Dec 22
Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX019
4:08pm
8-K
tt9ziregtialfz ww9f
9 Nov 22
Nkarta Reports Third Quarter 2022 Financial Results and Corporate Highlights
4:03pm
8-K
q7ntv91ddpkb0a
11 Aug 22
Nkarta Reports Second Quarter 2022 Financial Results and Corporate Highlights
4:10pm
8-K
aa4u7 0xyf2ndbwe7vr
10 Jun 22
Submission of Matters to a Vote of Security Holders
4:15pm
8-K
edl51e6r9xh7 n7
16 May 22
Nkarta Appoints David R. Shook, MD, as Vice President, Clinical Development
4:09pm
8-K
h52pc1i3l18t1ns
12 May 22
Nkarta Reports First Quarter 2022 Financial Results and Corporate Highlights
4:09pm
8-K
j4qqm28c0flzsmc05aly
28 Apr 22
Other Events
4:20pm
8-K
u6olhi
25 Apr 22
Nkarta Announces Positive Preliminary Dose Finding Data for Two Lead Engineered Natural Killer Cell Programs
7:52am
8-K
wqtka8dc9k7f
22 Apr 22
Nkarta to Host Conference Call Highlighting Preliminary Clinical Data from
4:17pm
8-K
ixebpdi ful4kdtoc
29 Mar 22
Nkarta Appoints Manufacturing Technology Executive, Angela Thedinga, to Board of Directors
8:11am
8-K
z4m9y3o
17 Mar 22
Nkarta Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights
4:11pm
8-K
wuuy8h p74j94m
10 Nov 21
Nkarta Reports Third Quarter 2021 Financial Results and Business Update
4:14pm
8-K
cyw6am6orcxwlzwd
22 Oct 21
Entry into a Material Definitive Agreement
4:13pm
8-K
rsk4mss eqn8h
7 Oct 21
Nkarta Announces Updates to NKX019 and NKX101 Clinical Development Programs
4:09pm
8-K
xbsra4yo6mewd 7r
12 Aug 21
Nkarta Reports Second Quarter 2021 Financial Results and Business Progress
4:19pm
8-K
lrw ql30vcztnx7
14 Jul 21
Entry into a Material Definitive Agreement
7:07am
8-K
fbtryuqe4sx1yc7kprfq
15 Jun 21
Submission of Matters to a Vote of Security Holders
4:11pm
8-K
b1affm8p2jsh84
13 May 21
Nkarta Reports First Quarter 2021 Financial Results and Business Progress
4:18pm
8-K
erboqail
6 May 21
CRISPR Therapeutics and Nkarta Announce Global Collaboration to Develop Gene-Edited Cell Therapies for Cancer
4:24pm
8-K
k66jcjibm xh1m
28 Apr 21
Nkarta Receives NKX019 IND Clearance from U.S. Food and Drug Administration for Treatment of Relapsed/Refractory B Cell Malignancies
8:07am